Krystal Biotech, Inc. (KRYS)
347.00
+1.45
(+0.42%)
USD |
NASDAQ |
Sep 11, 16:00
346.79
-0.21
(-0.06%)
After-Hours: 20:00
Krystal Biotech Price to Book Value : 7.556 for Sept. 11, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 7.556 |
| September 10, 2026 | 7.525 |
| September 09, 2026 | 7.580 |
| September 08, 2026 | 7.649 |
| September 04, 2026 | 7.801 |
| September 03, 2026 | 8.089 |
| September 02, 2026 | 8.040 |
| September 01, 2026 | 7.923 |
| August 31, 2026 | 7.825 |
| August 28, 2026 | 7.653 |
| August 27, 2026 | 7.784 |
| August 26, 2026 | 7.834 |
| August 25, 2026 | 7.756 |
| August 24, 2026 | 7.441 |
| August 21, 2026 | 7.547 |
| August 20, 2026 | 7.339 |
| August 19, 2026 | 7.476 |
| August 18, 2026 | 7.247 |
| August 17, 2026 | 7.311 |
| August 14, 2026 | 7.235 |
| August 13, 2026 | 7.150 |
| August 12, 2026 | 7.248 |
| August 11, 2026 | 7.122 |
| August 10, 2026 | 7.221 |
| August 07, 2026 | 7.109 |
| Date | Value |
|---|---|
| August 06, 2026 | 7.027 |
| August 05, 2026 | 7.094 |
| August 04, 2026 | 7.072 |
| August 03, 2026 | 6.806 |
| July 31, 2026 | 7.428 |
| July 30, 2026 | 7.988 |
| July 29, 2026 | 7.911 |
| July 28, 2026 | 7.931 |
| July 27, 2026 | 7.661 |
| July 24, 2026 | 7.299 |
| July 23, 2026 | 7.132 |
| July 22, 2026 | 7.334 |
| July 21, 2026 | 7.383 |
| July 20, 2026 | 7.387 |
| July 17, 2026 | 7.727 |
| July 16, 2026 | 7.443 |
| July 15, 2026 | 7.627 |
| July 14, 2026 | 7.391 |
| July 13, 2026 | 7.914 |
| July 10, 2026 | 7.966 |
| July 09, 2026 | 8.084 |
| July 08, 2026 | 8.175 |
| July 07, 2026 | 8.026 |
| July 06, 2026 | 8.159 |
| July 02, 2026 | 8.167 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| TG Therapeutics, Inc. | 13.66 |
| Cytokinetics, Inc. | -- |
| Alnylam Pharmaceuticals, Inc. | 24.56 |
| Exelixis, Inc. | 7.576 |
| Regeneron Pharmaceuticals, Inc. | 2.548 |
Price to Book Value Related Metrics
| PE Ratio | 43.49 |
| PS Ratio | 23.88 |
| PEG Ratio | 0.6977 |
| Price to Free Cash Flow | 40.80 |
| Price | 347.00 |
| Earnings Yield | 2.30% |
| Market Cap | 10.27B |
| PEGY Ratio | 0.6977 |
| Operating PE Ratio | 53.19 |
| Normalized PE Ratio | 43.49 |